1094546-99-2Relevant academic research and scientific papers
QUINOLIN-2(1H)-ONE INHIBITORS OF LATE SV40 FACTOR
-
, (2022/03/14)
The present invention is directed to compositions, methods and kits for treatment of cancer, e.g., hepatocellular carcinoma (HCC). In some embodiments, the present invention discloses the use of a small-molecule compounds of Formula (I) to inhibit tubulin acetylation, to inhibit cell migration, or to modulate cell compaction.
SMALL-MOLECULE INHIBITORS FOR THE Β-CATENIN/B-CELL LYMPHOMA 9 PROTEIN?PROTEIN INTERACTION
-
Page/Page column 156, (2021/04/01)
Disclosed are inhibitors for the β-catenin/B-cell lymphoma 9 interaction. The inhibitors are selective for β-catenin/B-cell lymphoma 9 over β-catenin/ E-cadherin PPI interaction. Methods of using the disclosed compounds to treat cancer are also disclosed.
GPR35 MODULATORS
-
Paragraph 00177, (2020/08/13)
Described herein are GPR35 modulators and methods of using these compounds in the treatment of diseases, disorders or conditions. Also described herein are pharmaceutical compositions containing such compounds.
